Cancer Research: Mini-Antibodies Reactivate the Guardian of the Genome
A research consortium has developed mini-antibodies that can reactivate mutated p53, a key tumor suppressor protein. These DARPins bind selectively to p53 mutants, restoring stability and functionality, making them potentially useful against various types of tumors.
SourceGoethe University Frankfurt·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateApr 29, 2026